Cue Biopharma (CUE) director receives grant of 24,400 stock options

Rhea-AI Filing Summary

Cue Biopharma director Peter A. Kiener reported a new stock option grant dated 01/02/2026. He received a stock option for 24,400 shares of Cue Biopharma common stock with an exercise price of $0.34 per share, recorded as an acquisition of derivative securities. The option was granted under the company’s Director Compensation Policy and is scheduled to become fully exercisable on the first anniversary of the grant date, with an expiration date of 01/01/2036. Following this grant, Kiener beneficially owns 24,400 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kiener Peter A

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.34	01/02/2026		A		24,400(1)		(2)	01/01/2036	Common Stock	24,400	$0.0	24,400	D

Explanation of Responses:

1. Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

2. This stock option becomes fully exercisable on the first anniversary of the grant date.

	/s/ Peter A Kiener by Colin Sandercock, attorney-in-fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cue Biopharma (CUE) report for Peter A. Kiener?

Cue Biopharma reported that director Peter A. Kiener received a grant of a stock option for 24,400 shares of common stock on 01/02/2026.

What is the exercise price of Peter A. Kiener’s new Cue Biopharma stock options?

The reported stock option grant to Peter A. Kiener has an exercise price of $0.34 per share for the underlying Cue Biopharma common stock.

When do Peter A. Kiener’s Cue Biopharma stock options vest and expire?

The filing states that this stock option becomes fully exercisable on the first anniversary of the 01/02/2026 grant date and has an expiration date of 01/01/2036.

How many Cue Biopharma derivative securities does Peter A. Kiener own after this transaction?

After the reported transaction, Peter A. Kiener beneficially owns 24,400 stock options as derivative securities, held directly.

Was the Cue Biopharma option grant to Peter A. Kiener part of a director compensation plan?

Yes. A footnote explains that the 24,400-share stock option award was granted pursuant to Cue Biopharma’s Director Compensation Policy.

Is Peter A. Kiener a director or officer of Cue Biopharma in this Form 4 filing?

The filing identifies Peter A. Kiener as a director of Cue Biopharma and not as an officer or 10% owner.